BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31810765)

  • 1. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
    Gondek LP; DeZern AE
    Lancet Haematol; 2020 Jan; 7(1):e73-e81. PubMed ID: 31810765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
    DeZern AE; Malcovati L; Ebert BL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
    Tang G; Medeiros LJ; Wang SA
    Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
    Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
    Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
    Osman A; Patel JL
    Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
    Sperling AS; Gibson CJ; Ebert BL
    Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
    Sujobert P; Largeaud L; Jamilloux Y; Heiblig M; Kosmider O
    Expert Rev Hematol; 2023; 16(7):495-499. PubMed ID: 37119011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Hematopoiesis of Indeterminate Potential.
    Heuser M; Thol F; Ganser A
    Dtsch Arztebl Int; 2016 May; 113(18):317-22. PubMed ID: 27215596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clonal haematopoiesis: A concise review].
    Danlos FX; Papo M; Micol JB
    Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
    Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
    Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide.
    Xie Z; DeZern AE
    NEJM Evid; 2023 May; 2(5):EVIDe2300053. PubMed ID: 38320009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
    Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
    Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
    Malcovati L; Cazzola M
    Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
    Bejar R
    Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
    Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
    Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICUS/CCUS/CHIP: basics & beyond.
    Jain M; Tripathi A
    Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
    Caponetti GC; Bagg A
    Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).
    Steensma DP
    Curr Hematol Malig Rep; 2019 Dec; 14(6):536-542. PubMed ID: 31696381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.